2006
Clinical Experience With Denileukin Diftitox (ONTAK)
Foss F. Clinical Experience With Denileukin Diftitox (ONTAK). Seminars In Oncology 2006, 33: 11-16. PMID: 16516670, DOI: 10.1053/j.seminoncol.2005.12.017.Peer-Reviewed Original ResearchConceptsIL-2 receptorCutaneous T-cell lymphomaT-cell lymphomaDenileukin diftitoxIntermediate affinity IL-2 receptorsHuman IL-2 receptorChronic lymphocytic leukemiaActivated T lymphocytesDiphtheria toxinClinical profileHodgkin's lymphomaHematologic disordersT lymphocytesLymphocytic leukemiaB cellsClinical experienceB lymphocytesLymphomaCytocidal actionNumber of leukemiasDiftitoxHigh affinity formCellular protein synthesisReceptorsLymphocytes
2002
Immunologic mechanisms of antitumor activity
Foss FM. Immunologic mechanisms of antitumor activity. Seminars In Oncology 2002, 29: 5-11. PMID: 12068382, DOI: 10.1053/sonc.2002.33076.Peer-Reviewed Original ResearchConceptsAntigen-presenting cellsCytotoxic T lymphocytesEffector cellsCostimulatory moleculesT lymphocytesImmune responseTumor antigensImmune effectorsTumor-specific cytotoxic T lymphocytesTumor cellsMHC complexesEffector cell expansionInadequate immune responseImmune effector cellsHost immune surveillanceAntigen class ICostimulatory adhesion moleculesTumor-associated peptidesT cell receptorOverall immunosuppressionCytokine therapyImmunologic mechanismsAdvanced cancerAntitumor responseTumor escapeInterleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines
Cosenza L, Gorgun G, Urbano A, Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cellular Signalling 2002, 14: 317-325. PMID: 11858939, DOI: 10.1016/s0898-6568(01)00245-5.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsCell LineEpithelial CellsHematopoietic Stem CellsHumansImmunoblottingInterleukin Receptor Common gamma SubunitJanus Kinase 3Lung NeoplasmsNeoplasmsNuclease Protection AssaysProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-fynReceptors, Interleukin-7RNA, MessengerSignal TransductionTissue DistributionTranscription, GeneticTumor Cells, CulturedConceptsIL-7R mRNABrain tumor cell linesIL-7RIL-7RalphaCell linesTumor cell linesInterleukin-7 receptor expressionReceptor-directed therapyNational Cancer Institute tumor panelBreast cancer cell linesReceptor gamma chainLung cancer cellsInterleukin-2 receptor gamma chainHeterodimeric complex consistingS1 nuclease protection assaysCellular differentiation processesEpithelial tumor cellsCancer cell linesNuclease protection assaysS1 nuclease protectionLung cancerSerine residue phosphorylationReceptor expressionNeoplastic cell linesInterleukin-7Diphtheria fusion protein therapy of chemoresistant malignancies.
Frankel AE, Rossi P, Kuzel TM, Foss F. Diphtheria fusion protein therapy of chemoresistant malignancies. Current Cancer Drug Targets 2002, 2: 19-36. PMID: 12188918, DOI: 10.2174/1568009023333944.Peer-Reviewed Original ResearchConceptsTargeted toxinsFusion protein therapyDiphtheria toxinChemotherapy-refractory cancersSelective ligandsTumor-selective ligandsChemoresistant diseaseCombination chemotherapyNeoplastic stem cellsRefractory cancerChemoresistant malignancyGroup IPseudomonas exotoxinWidespread cancerTherapyCell functionCancer therapyAntiviral proteinProtein therapyCancerToxin